{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:15:28Z","timestamp":1789168528734,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2026,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Introduction<\/jats:title>\n Dolutegravir (DTG) is a key antiretroviral (ARV) drug for children living with HIV, but no specific formulation is available for neonates (<28 days old). One of the DTG formulations evaluated in the PETITE\u2010DTG trial was a novel 5\u00a0mg oral DTG dispersible film (DTG\u2010Film). Acceptability to end\u2010users is essential when introducing new ARV drugs. We report on the experiences of mothers and health workers related to the DTG\u2010Film.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n PETITE\u2010DTG was a phase I\/II, open\u2010label two\u2010stage study evaluating the pharmacokinetics, safety and acceptability of two paediatric DTG formulations in term neonates in South Africa. In the multi\u2010dose stage, 43 term neonates born to women with HIV were randomized to receive either the 5\u00a0mg DTG\u2010Film or half of a 10 mg DTG dispersible tablet, in addition to zidovudine syrup prophylaxis, for 28 days. In\u2010depth interviews were conducted in a sub\u2010set of mothers whose neonates received DTG\u2010Film (at three time points) and with health workers (at two time points). Thematic analysis was employed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Data were collected (September 2023\u2013October 2024) from 16 virologically suppressed mothers (median age: 38 years) whose neonates received DTG\u2010Film and six female health workers (median age: 47 years) involved in the study. Usability was described positively\u2014with participants highlighting ease of administration, quick dissolution, accurate dosing with no spillage and convenient packaging. Some mothers were initially hesitant due to unfamiliarity with the film, but after 1\u20132 doses, most reported liking or preferring the DTG\u2010Film above other known ARV formulations. The film integrated well into households, was supported by family members and was considered discreet, helping to avoid unintentional HIV\u2010status disclosure. Previous experience with neonatal ARV drugs and trust in health workers supported acceptability. Health workers noted DTG\u2010Film was potentially fit for use in public health settings, where other formulations require manipulation prior to administration. Health workers played a key role in reassuring mothers that the \u201cpaper\u201d was indeed medicine.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Mothers and health workers found the new DTG\u2010Film acceptable for neonatal use. While initial hesitancy was noted, acceptability increased with use. Targeted peer support and engagement with mothers and health workers will be essential to familiarize end\u2010users with the novel DTG\u2010Film.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/jia2.70104","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:05:09Z","timestamp":1781874309000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acceptability of a Dolutegravir Oral Dispersible Film in Term Neonates Born to Mothers Living With HIV"],"prefix":"10.1002","volume":"29","author":[{"given":"Lario","family":"Viljoen","sequence":"first","affiliation":[{"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Purdy","sequence":"additional","affiliation":[{"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verah","family":"Luke","sequence":"additional","affiliation":[{"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha du","family":"Toit","sequence":"additional","affiliation":[{"name":"Family Centre for Research with Ubuntu\u00a0(FAMCRU), Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Groenewald","sequence":"additional","affiliation":[{"name":"Family Centre for Research with Ubuntu\u00a0(FAMCRU), Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindee","family":"Ganger","sequence":"additional","affiliation":[{"name":"Family Centre for Research with Ubuntu\u00a0(FAMCRU), Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke C.","family":"Hesseling","sequence":"additional","affiliation":[{"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Garcia\u2010Prats","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine and Public Health University of Wisconsin\u2010Madison Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[{"name":"AMS\u2010PHPT Research Collaboration, Department of Medical Technology, Faculty of Associated Medical Sciences Chiang Mai University Chiang Mai Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrie","family":"Bekker","sequence":"additional","affiliation":[{"name":"Family Centre for Research with Ubuntu\u00a0(FAMCRU), Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organisation Global Health Sector Strategies on Respectively HIV Viral Hepatitis and Sexually Transmitted Infections for the Period 2022\u20132030(2022)."},{"key":"e_1_2_10_3_1","unstructured":"UNICEF HIV\u2014Elimination of Mother\u2010to\u2010Child Transmission(2024)."},{"key":"e_1_2_10_4_1","unstructured":"Thembisa Project Thembisa Model Version 4.8: National and Provincial Outputs(2025)."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00121-7"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v16i1.361"},{"key":"e_1_2_10_7_1","volume-title":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach","author":"World Health Organization","year":"2021"},{"key":"e_1_2_10_8_1","volume-title":"Paediatric Abacavir\/Lamivudine\/Dolutegravir (pALD) Fixed\u2010Dose Combination: Introduction and Rollout Planning Considerations for National Programmes","author":"World Health Organization","year":"2023"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00239-5"},{"key":"e_1_2_10_10_1","unstructured":"US Food & Drug Administration Tentative Approval of Dolutegravir Oral Film 5\u00a0mg and 10\u00a0mg(2023)https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/215319Orig1s000TAltr.pdf."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2021036885"},{"key":"e_1_2_10_12_1","unstructured":"S. I.Watts Development of Thin Film Oral Drug Delivery Devices for Use in Paediatric and Palliative Care Patient Populations(2016)."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.03.018"},{"issue":"1","key":"e_1_2_10_14_1","first-page":"192","article-title":"Intrapartum Human Immunodeficiency Virus Transmission Rate in a Central Hospital in the Western Cape Province After Universal Antiretroviral Therapy Roll\u2010Out","volume":"35","author":"Der Merwe T. A.","year":"2020","journal-title":"Southern African Journal of Infectious Diseases"},{"issue":"1","key":"e_1_2_10_15_1","first-page":"1","article-title":"The 2022 Antenatal HIV Sentinel Survey: Key Findings","volume":"2013","author":"Kufa\u2010Chakezha T.","year":"2023","journal-title":"Public Health Bulletin South Africa"},{"key":"e_1_2_10_16_1","unstructured":"N.Davies J.Nel andC.Wattrus Updated South African ART Guidelines for Use of Dolutegravir (DTG) in Pregnant Women and Women of Childbearing Potential (WOCP)(2021)."},{"key":"e_1_2_10_17_1","unstructured":"South African National Department of Health Guideline for Vertical Transmission Prevention of Communicable Infections(2023)."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1468794119884806"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001267"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.01.003"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-015-0313-1"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2017.1370512"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-10078-6"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.70104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:47:16Z","timestamp":1789166836000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.70104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":22,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/jia2.70104"],"URL":"https:\/\/doi.org\/10.1002\/jia2.70104","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70104"}}